Case T-470/13: Judgment of the General Court of 8 September 2016 — Merck v Commission (Competition — Agreements, decisions and concerted practices — Market for antidepressant medicinal products containing the active pharmaceutical ingredient citalopram — Concept of restriction of competition ‘by object’ — Potential competition — Generic medicinal products — Barriers to market entry resulting from the existence of patents — Agreements concluded between a patent holder and a generic undertaking — Error of law — Error of assessment — Imputability of infringements — Liability of a parent company for infringements of the competition rules committed by its subsidiaries — Legal certainty — Reasonable time — Fines)
Date: 2016-09-08
Institutions: General Court
Subjects: EU competition policy, cartel, control of restrictive practices, fine, generic drug, parent company, patent, principle of legal certainty, restriction on competition, subsidiary








C_2016383EN.01001201.xml










17.10.2016   


EN


Official Journal of the European Union


C 383/12





Judgment of the General Court of 8 September 2016 — Merck v Commission
(Case T-470/13) (1)

((Competition - Agreements, decisions and concerted practices - Market for antidepressant medicinal products containing the active pharmaceutical ingredient citalopram - Concept of restriction of competition ‘by object’ - Potential competition - Generic medicinal products - Barriers to market entry resulting from the existence of patents - Agreements concluded between a patent holder and a generic undertaking - Error of law - Error of assessment - Imputability of infringements - Liability of a parent company for infringements of the competition rules committed by its subsidiaries - Legal certainty - Reasonable time - Fines))
(2016/C 383/16)
Language of the case: English

Parties


Applicant: Merck KGaA (Darmstadt, Germany) (represented initially by B. Bär-Bouyssière, K. Lillerud, L. Voldstad, B. Marschall, P. Sabbadini, R. De Travieso, M. Holzhäuser and S. O, lawyers, M. Marelus, Solicitor, and R. Kreisberger and L. Osepciu, Barristers, and subsequently by B. Bär-Bouyssière, L. Voldstad, M. Holzhäuser, A. Cooke, M. Gampp, lawyers, M. Marelus, R. Kreisberger and L. Osepciu)

Defendant: European Commission (represented initially by J. Bourke, F. Castilla Contreras and T. Vecchi, and subsequently by F. Castilla Contreras, T. Vecchi, B. Mongin and C. Vollrath, acting as Agents, assisted by S. Kingston, Barrister)

Intervener in support of the defendant: Generics (UK) Ltd (Potters Bar, United Kingdom) (represented initially by G. Drauz, M. Rosenthal and B. Record, lawyers, and subsequently by G. Drauz and M. Rosenthal)

Re:

Application for annulment of Commission Decision C(2013) 3803 final of 19 June 2013 relating to a proceeding under Article 101 [TFEU] and Article 53 of the EEA Agreement (Case AT.39226 — Lundbeck), and for reduction of the amount of the fine imposed on the applicant by that decision.

Operative part of the judgment

The Court:






1.


Dismisses the action;










2.


Orders Merck KGaA to bear its own costs and those incurred by the European Commission;










3.


Orders Generics (UK) Ltd to bear its own costs.






(1)  OJ C 325, 9.11.2013.